Kratom’s Split Over 7-OH Crisis

A decade after kratom advocates fought off a federal ban, a bitter rift has erupted as the same community now faces backlash over 7-hydroxymitragynine—potent, opioid-like extracts sold in gummies and shots. Critics warn these products are dangerously misleading, causing overdoses and withdrawal, while industry backers insist they’re just stronger kratom. Federal officials label the sector “sinister,” sparking accusations of conflicts of interest and state-level bans. Scientists fear a federal crackdown could stifle research into kratom’s potential for treating opioid addiction, leaving regulators caught between public safety and access to a controversial but promising compound. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/05207b497e072236